The IL27 Knockout TE1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human TE1 esophageal squamous cell carcinoma cell line, designed for targeted disruption of the IL27 gene. This polyclonal format enables robust gene-level perturbation while maintaining genetic heterogeneity, making it ideal for pooled functional screens and population-level analyses. The loss-of-function model bypasses clonal selection artifacts, providing a more physiologically relevant representation of IL27 deficiency in a cancer epithelial context.
The TE1 cell line originates from a human esophageal squamous cell carcinoma, an aggressive malignancy with limited therapeutic options. TE1 cells retain epithelial characteristics and are extensively used to study esophageal cancer biology, including proliferation, invasion, and interactions with the tumor microenvironment. As an IL27-expressing line, TE1 provides a clinically pertinent host to investigate the cytokine’s autocrine and paracrine effects on tumor cell signaling and immune modulation.
IL27 is a heterodimeric cytokine composed of EBI3 and p28 subunits that engages a receptor complex of IL27RA and gp130. Ligand binding triggers activation of JAK1, JAK2, and TYK2, resulting in phosphorylation of STAT1 and STAT3. These STATs regulate transcription of immune targets including TBX21/T-bet, IFNG, IL10, and CD274/PD-L1, with feedback control by SOCS1/SOCS3. Upstream, IL27 is induced by TLR agonists, IFN-??, NF-??B, IRF1, and IRF3, linking innate and adaptive immunity.
In esophageal squamous cell carcinoma, IL27-driven STAT1/STAT3 signaling may promote immune evasion by upregulating PD-L1 and altering the cytokine milieu. This polyclonal knockout model allows direct functional dissection of how IL27 loss reshapes tumor-intrinsic signaling and crosstalk with immune cells. It is particularly suited for investigating the interplay between cytokine signaling, immune checkpoint molecule expression, and carcinoma cell behavior in coculture systems with T lymphocytes or other immune effectors.
This knockout resource supports assays such as western blotting for phospho-STAT1/STAT3, RT-qPCR of IL10, CD274, TBX21, flow cytometry for PD-L1, immune coculture with T cells, proliferation/migration assays, RNA-seq, and ELISA. It enables functional genomics and drug screening in an IL27-deficient background. For further details, contact Ascent Research.
